Combination therapies comprising apremilast and tyk2 inhibitors
AssigneeCelgene Corporation
InventorsPeter Henry Schafer, Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr, Te-chen Tzeng
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
Claims30
A method of treating a disease or disorder responsive to the inhibition of phosphodiesterase type 4 (PDE4) in a subject, comprising administering to the subject a therapeutically effective amount of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide, or a pharmaceutically acceptable salt thereof;
- and a therapeutically effective amount of a tyrosine kinase 2 (Tyk2) inhibitor of the formula:
- or a pharmaceutically acceptable salt thereof.
2-5. (canceled)
7-9. (canceled)
12-20. (canceled)
(canceled)
27-35. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising a therapeutically effective amount of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide, or a pharmaceutically acceptable thereof;
- and a therapeutically effective amount of a Tyk2 inhibitor of the formula:
- or a pharmaceutically acceptable salt thereof.
51-62. (canceled)
Dependencies are inferred from the claim text.